ライフサイエンスコーパス: curative

1 ion in its early stages, when surgery can be curative.

2 such that only the removal of the implant is curative.

3 mbination therapies have the potential to be curative.

4 l and improve symptoms but are typically not curative.

5 unpredictable clinical efficacy, and none is curative.

6 e latent HIV reservoir and are therefore not curative.

7 ly, no treatment is universally effective or curative.

8 rvival and alleviate symptoms but are rarely curative.

9 most common treatment, although it is seldom curative.

10 lls to induce remission, but is infrequently curative.

11 apeutic interventions palliative rather than curative.

12 hly potent trypanocide in vitro and displays curative activity in animal models of acute and CNS-stag

13 JAK inhibition is not curative and fails to induce a persistent response in mo

14 Future studies should focus on curative and individualised treatment regimens to improv

15 Radiotherapy (RT), an established curative and palliative cancer treatment, exerts potent

16 ed in >50% of patients with cancer, both for curative and palliative purposes.

17 However, LCSD is not curative and patient selection will be critical when pot

18 y areas that need further research to inform curative and preventive measures against HIV/AIDS.

19 for next-generation antimalarials to be both curative and transmission-blocking necessitates the iden

20 isconceptions that palliative treatments are curative, and disputes about potentially inappropriate o

21 r chronic lymphocytic leukemia (CLL) are not curative, and the search for new therapeutic modalities

22 rospective, multicenter study evaluating all curative antibiotic therapies prescribed over 2 consecut

23 thrombopenia [< 150 G/L], and preventive or curative anticoagulation) at the time of the biopsy were

24 tionality and recall responses that promoted curative antitumor immunity after adoptive transfer.

25 tudy of hepatitis B virus and development of curative antivirals are hampered by a scarcity of models

26 ulatory T cell (Treg) therapy is a potential curative approach for a variety of immune-mediated condi

27 Therefore, this curative approach should no longer be restricted to pati

28 V)-delivered meganucleases, as a potentially curative approach to treat latent HSV infection.

29 ic cell transplantation (HCT) is the primary curative approach, with the goal of correcting the under

30 ponse rates in several lymphomas, but is not curative as monotherapy.

31 cyclines are a highly effective component of curative breast cancer chemotherapy but are associated w

32 Direct-acting antiviral therapy is now curative, but it is estimated that only 20% of individua

33 topoietic stem cell transplant (HSCT) can be curative, but suitable donors are often unavailable.

34 cular, we identify S-MGB-234, compound 7, as curative by using two applications of 50 mg/kg intraperi

35 Curative cancer therapies are uncommon and nearly always

36 idence for the 50 year old hypothesis that a curative cancer therapy can be constructed on the basis

37 cies extinctions as an alternative model for curative cancer therapy.

38 team-based approach to balance the need for curative cancer treatment while preventing increased car

39 ting cancer stem cells remain challenges for curative cancer treatment.

40 apy is a critical component of many current, curative cancer treatments, yet it is accompanied by una

41 omeostasis throughout life and underlies the curative capacity of clinical HSC transplantation therap

42 ter-tolerated, time-limited, and potentially curative chemo-free treatment regimens.

43 g the study period, 504 patients underwent a curative colectomy for a stage II OCC.

44 Short-course, oral, curative, direct-acting antiviral regimens have transfor

45 etastases and myeloma bone disease is rarely curative, disease control is often possible for many yea

46 oving difficult, despite the availability of curative drug treatments.

47 eutics to eradicate MDS HSCs and augment the curative effect of allogeneic HCT for this disease.

48 le for SMARCD2 in human myelopoiesis and the curative effect of hematopoietic stem cell transplantati

49 We here demonstrate suppressive but not curative effect of remdesivir in an immunocompromised pa

50 AR-expressing T cells against CD19 can cause curative effects in leukemia and lymphoma and is approve

51 Curative effects in vivo were only observed in xenograft

52 The protective and curative effects of EPL were demonstrated on tomato plan

53 s) occurred in settings with near-perfect SP curative efficacy (>99%) based on the most recent estima

54 h against multidrug-resistant parasites; (2) curative efficacy after oral administration in an erythr

55 The radical curative efficacy in vivax malaria of 7-day high-dose pr

56 rmed to compare the tolerability and radical curative efficacy of 7-day versus 14-day high-dose prima

57 er GI Cancer Audit who underwent potentially curative esophageal carcinoma surgery in 2011 to 2018, w

58 s, early-IUGT in macaques produces sustained curative expression related significantly to integrated

59 tly, this immunotherapeutic regimen was also curative for large established mouse Renca and EG7 tumor

60 AR) is an approved immunotherapy that may be curative for some hematological cancers.

61 ty worldwide and prognosis after potentially curative gastrectomy remains poor.

62 e disease, but there is current optimism for curative gene transfer strategies to induce expression o

63 than untreated patients received potentially curative HCC therapy for recurrent HCC (32.0% vs 24.6%)

64 CK8) deficiency was proposed for potentially curative hematopoietic stem cell transplantation (HSCT),

65 ociated anemia whose cancer treatment is not curative in intent and whose hemoglobin has declined to

66 c hematopoietic stem cell transplantation is curative in myelofibrosis, and current prognostic scorin

67 HSCT is curative in patients with CD40L deficiency, with improve

68 ct cancers, and liver transplantation can be curative in selected patients with perihilar cholangioca

69 m GC who were treated with complete CRS with curative intent (no residual nodules > 2.5 mm) at 19 Fre

70 ive patients treated for a stage II OCC in a curative intent (with primary tumor resection) between J

71 Patients were treated with curative intent and received IC before definitive locore

72 lled in the study and those not treated with curative intent at the time of bloodstream infection ons

73 esophagectomy or gastrectomy for cancer with curative intent between 2011 and 2016 and were registere

74 Patients (2013-2018) treated with curative intent by open surgery were studied.

75 , including disease-related (acute leukemia, curative intent chemotherapy), laboratory-related (plate

76 Although patients undergo procedures with curative intent for early-stage hepatocellular carcinoma

77 W policy were able to undergo treatment with curative intent for local regrowth.

78 ITICS trial who underwent a gastrectomy with curative intent in a Dutch hospital were included in the

79 Hepatoblastoma treatment with curative intent requires surgical resection, but only ab

80 ancer diagnosed from 2010 to 2015 undergoing curative intent resection were selected from the Nationa

81 ts >=18 years of age with PMBCL treated with curative intent rituximab-chemotherapy were identified.

82 e survival (CDFS) for patients who underwent curative intent surgery for adrenocortical carcinoma (AC

83 oint at which clinical treatment shifts from curative intent to extending survival.

84 of minimal residual disease monitoring after curative intent treatment for earlier detection of disea

85 for adjuvant chemotherapy after surgery with curative intent were included in our double-blind phase

86 ents with biliary tract cancer resected with curative intent were randomly assigned to the capecitabi

87 lung cancer (NSCLC) who undergo surgery with curative intent will relapse within 5 years(1,2).

88 tic resection, or, less commonly, both) with curative intent, and an Eastern Cooperative Oncology Gro

89 HCC resection or liver transplantation, with curative intent, were used.

90 nts are eligible for surgical resection with curative intent, with 5-year overall survival of less th

91 new options for cell-based therapeutics with curative intent.

92 o more definitive consolidation therapy with curative intent.

93 HL) or aggressive non-HL (ANHL) treated with curative intent.

94 mized between open and MI esophagectomy with curative intent.

95 nts with UTUCs after nephroureterectomy with curative intent.

96 esection of an ampullary adenocarcinoma with curative intent.

97 r defining response with (18)F-FDG PET after curative-intent chemoradiation for non-small cell lung c

98 All patients were treated with curative-intent chemoradiotherapy (CRT).

99 for advanced stage, who were considered for curative-intent first-line therapy.

100 Among 655 adults who received curative-intent induction or reinduction chemotherapy wi

101 C treated at a specialist cancer centre with curative-intent non-surgical treatment who underwent bas

102 al recurrence after radical prostatectomy or curative-intent radiotherapy were included in this prosp

103 low us to expand the population eligible for curative-intent radiotherapy, optimise and customise rad

104 erately differentiated PanNETs who underwent curative-intent resection at 9-institutions from 2000 to

105 erize the patterns of first recurrence after curative-intent resection for pancreatic adenocarcinoma

106 Consecutive patients undergoing curative-intent surgery for esophageal cancer from 2011

107 Curative-intent surgery for potentially resectable PDAC

108 Although nearly one-quarter of curative-intent surgery patients were from high SED neig

109 SED impacted surgical evaluation, receipt of curative-intent surgery, postoperative complications, re

110 opioid use among cancer patients undergoing curative-intent surgery.

111 ive opioid use in cancer patients undergoing curative-intent surgery.

112 II small-cell lung cancer who have undergone curative-intent treatment.

113 An effective curative intervention could prevent new infections, over

114 ese modalities, and surgery remains the only curative intervention for localized disease.

115 lifelong medication, developing an effective curative intervention is now a global priority.

116 Evaluations of HIV curative interventions require reliable and efficient qu

117 he next frontier in RA is the development of curative interventions, for example, reprogramming T cel

118 on ART is a high priority for the design of curative interventions.

119 plications for the design and measurement of curative interventions.

120 ell as downstaging liver-directed therapy to curative liver transplantation (LT).

121 ier against the widespread use of HSCTs as a curative modality.

122 SN22 is an effective and curative multivalent macromolecular agent in multiple so

123 efined either as different treatment intent (curative, noncurative, or unable to determine) or as dif

124 ignant regional lymph nodes (MRLN) precludes curative oncologic resection or liver transplantation fo

125 gnant regional lymph nodes (MRLNs) precludes curative oncological resection or liver transplantation

126 transplantation remains the only potentially curative option and is accessible to only a small number

127 The only curative option for CMML remains allogeneic stem cell tr

128 toinflammation in PAMI syndrome and may be a curative option for other proline-serine-threonine phosp

129 anticancer therapy, providing a potentially curative option for patients who are refractory to stand

130 cell transplantation, which remains the only curative option, and chemotherapy, both of which are fea

131 oietic stem cell transplantation is the only curative option, but a high risk of graft failure and po

132 nd liver transplantation represents the only curative option.

133 remental survival benefit of LT versus other curative options (resection or ablation) due to shunting

134 complications, early management still lacks curative options and consists of adequate fluid resuscit

135 surgical resection or radiotherapy, but such curative options are limited in the setting of recurrent

136 LR and LT are the standard curative options for early HCC.

137 er death in men in America, and there are no curative options for metastatic castration-resistant pro

138 It enabled new curative options for patients with previous radiotherapy

139 ddition, (68)Ga-PSMA PET staging enabled new curative options in half the patients with previous radi

140 s that with increased awareness of effective curative options these disparities will decrease, and pe

141 mphocytic leukemia, can consistently achieve curative outcomes in nonpediatric cancers.

142 Here, we propose that curative outcomes may, nevertheless, be achieved by sequ

143 une 2014, patients who underwent potentially curative pancreatectomy for pancreatic ductal adenocarci

144 hope for better, disease-modifying, or even curative, pharmacological and non-pharmacological treatm

145 sease-initiating MDS HSCs, and thus have low curative potential and high relapse rates.

146 onditioning (RIC) regimens have extended the curative potential of allogeneic stem-cell transplantati

147 e toxicity limits the radiation dose and the curative potential of radiation therapy when treating la

148 s and treatment candidates with the greatest curative potential therefore requires determining the am

149 ers prophylactic, transmission blocking, and curative potential.

150 nvigorating cancer immunotherapies have near-curative potential.

151 ission remains the only reliable option with curative potential.

152 Women (age <85 years) having potentially curative primary breast cancer resections were randomise

153 f tumors from 30% of the mice, and conferred curative protection from tumor rechallenges, consistent

154 f the patient is a candidate for potentially curative pulmonary endarterectomy surgery.

155 TNM-stage migration and accordingly adapted curative radiotherapy options including ablative treatme

156 rapy is safe and does not impair delivery of curative radiotherapy or chemotherapy in HNSCC.

157 patients with LAPC may become candidates for curative resection following neoadjuvant therapy, and re

158 liced variant of MTA1, in patients receiving curative resection for HBV-HCC.

159 Consecutive patients who underwent curative resection for Stage III CRC from 1995 to 2012 a

160 res patterns of recurrence after potentially curative resection in lymph node-positive and lymph node

161 insula epilepsy can be identified and focal curative resection is possible.

162 Purpose After curative resection of gastric or gastroesophageal juncti

163 dy suggests that adjuvant chemotherapy after curative resection of stage II OCC may improve oncologic

164 state cancer often occur following attempted curative resection of the primary tumor, and up to 66% o

165 ected 102 patients with HBV-HCC and received curative resection retrospectively and examined the expr

166 neck cancer patients (n = 14) scheduled for curative resection were enrolled in a clinical trial eva

167 rence-free survival at 5 years after PanNETs curative resection, with improved accuracy over current

168 low growing pulmonary metastases amenable to curative resection.

169 ssue samples from 151 NSCLC patients who had curative resection.

170 risk factor for colorectal recurrence after curative resection.

171 of freedom from recurrence at 5 years after curative resection.

172 enefits of adjuvant systemic therapies after curative resection/ablation.

173 Nonetheless, a complete curative response following immunotherapy is observed on

174 erved motif of Rad50, resulted in an outlier curative response in a clinical trial.

175 of personalized medicine, offering hope for curative responses in patients with serious illnesses.

176 tch hospitals, who underwent DS or ER in the curative setting, were propensity-score matched in a 1:2

177 for PET in triaging men being considered for curative SRT.

178 Thus, this review will focus on possible curative strategies aimed at eliminating or crippling th

179 findings have implications for the design of curative strategies for HIV-1.

180 ew diagnostic, prophylactic, therapeutic and curative strategies is critical to address this burden b

181 cal limitation preventing the development of curative strategies is the lack of knowledge regarding m

182 Curative strategies that target the reservoir are being

183 cells is critical for developing successful curative strategies.

184 and should therefore be considered in future curative strategies.

185 T cells are an important component of HIV-1 curative strategies.

186 ebound and could be targeted for boosting in curative strategies.

187 tious HIV-1 and should be targeted by future curative strategies.IMPORTANCE HIV-1 persists as an inte

188 hemoglobinopathies has the potential to be a curative strategy available to all.

189 CAR T cells represent a potentially curative strategy for B cell malignancies.

190 bladder, ureter, or urethra not amenable to curative surgery and not candidates for cisplatin-based

191 Multivariable models were used in the curative surgery cohort to predict the impact of SED on

192 e breast cancer recurrence after potentially curative surgery compared with volatile anaesthesia (sev

193 s or other locations in the colorectum after curative surgery for primary CRC.

194 After curative surgery in a multimodal setting, the histologic

195 t breast cancer recurrence after potentially curative surgery is lower with regional anaesthesia-anal

196 Patients with BCR and candidates for curative surgery were excluded.

197 o early cancer detection and availability of curative surgical management.

198 Our study identifies a novel curative therapeutic approach that can prevent the devel

199 ection of HCC creates more opportunities for curative therapeutic interventions.

200 t immune response provide novel, potentially curative therapeutic opportunities and targets.

201 tant protein will be a pre-requisite for any curative therapeutic strategy.

202 will reveal molecular targets for developing curative therapeutics of chronic HBV infection.

203 n early stage are candidates for potentially curative therapies (local ablation, resection, or transp

204 Curative therapies are most successful when cancer is di

205 ncreatic cancer is often detected late, when curative therapies are no longer possible.

206 lindness and visual impairment worldwide, no curative therapies exist.

207 Currently, there are no curative therapies for this fatal disease.

208 ded to the general population, and intensive curative therapies have become the standard.

209 of neuromuscular diseases are well known, no curative therapies have been developed to date.

210 nosed at early stage and receive potentially curative therapies, such as surgical resection and liver

211 Many patients are not eligible for curative therapies, such as surgical resection of the tu

212 results in increased probability to undergo curative therapies.

213 voir for infectious virus and an obstacle to curative therapies.

214 in the absence of effective preventative or curative therapies.

215 ges, and is associated with lower receipt of curative therapy and with poorer survival, current socie

216 Curative therapy depends on control of the primary tumou

217 oietic stem cell transplantation (HSCT) is a curative therapy for blood and immune diseases with pote

218 tem cell transplantation is a cornerstone of curative therapy for high-risk and/or advanced hematolog

219 ll transplantation (alloSCT) is an important curative therapy for high-risk hematological malignancie

220 Curative therapy for metastatic cancers is equivalent to

221 system after transplantation(1), which is a curative therapy for numerous diseases including immunod

222 ate human epidermis after transplantation, a curative therapy for severe burns and, recently, disease

223 he potential of evoking memory response as a curative therapy for the treatment of CRC liver metastas

224 in Yoshihara et al., holds the promise of a curative therapy for this disease.

225 strong similarity to the empirically-derived curative therapy in childhood acute lymphocytic leukemia

226 Athough curative therapy is now available for hepatitis C virus

227 and suggest that development of a long-term curative therapy of prostate cancer may be possible by k

228 the clinical course, and offer prospects for curative therapy of sickle cell disease.

229 life-threatening pathogen that still lacks a curative therapy or vaccine.

230 nificantly higher before the commencement of curative therapy than after therapy.

231 an duration of persistence in the absence of curative therapy was 143 days (range, 21-228).

232 mediate or high grade, for which no standard curative therapy was available, an Eastern Cooperative O

233 ts with HCC who are eligible for potentially curative therapy with liver resection or ablation should

234 transplantation (HCT) has been considered a curative therapy, but the procedure has inherent complic

235 splantation (alloHSCT) is the only available curative therapy, with benefits derived from the antigen

236 ion people worldwide, HIV-1 infection has no curative therapy.

237 ients are otherwise eligible for potentially curative therapy.

238 tion of MDS HSCs is an important part of any curative therapy.

239 h may lead to novel strategies for improving curative therapy.

240 Treatment for bone metastases is not curative, therefore new adjuvant therapies which prevent

241 Even when curative, these approaches can be cosmetically and funct

242 ourteen of 44 (32%) participants underwent a curative treatment after TACE.

243 ependent predictor of tumor recurrence after curative treatment and all-cause mortality in patients w

244 The probability of patients receiving curative treatment and long-term survival increased from

245 gnostic tools for early detection nor does a curative treatment exist.

246 w stem cell transplantation is a potentially curative treatment for both malignant and nonmalignant d

247 for HBV therapeutic vaccination.IMPORTANCE A curative treatment for chronic hepatitis B must eliminat

248 Curative treatment for HCC resulted the only independent

249 ecting the combination of the opioid crisis, curative treatment for HCV infection, and mortality amon

250 cquired liver diseases and could represent a curative treatment for hemophilia A.

251 Despite the availability of curative treatment for hepatitis C virus (HCV) infection

252 oietic stem cell transplantation (HSCT) is a curative treatment for multiple disorders, but deficienc

253 The standard curative treatment for patients with esophageal cancer i

254 cell transplantation is the only potentially curative treatment for patients with myelodysplastic syn

255 the Whipple procedure) is the only potential curative treatment for periampullary tumours.

256 cell transplantation (HCT) remains the only curative treatment for this condition, but transplant su

257 transplantation (LT) has been proposed as a curative treatment in hereditary hemorrhagic telangiecta

258 cm) primary and metastatic liver tumors with curative treatment intent.

259 Currently, no curative treatment is available for early-to-intermediat

260 Currently, no curative treatment is available.

261 nce of chronic pancreatitis is rising and no curative treatment is available.

262 Currently, the only curative treatment is hematopoietic stem cell transplant

263 ymptomatic nature of the disease and lack of curative treatment modalities, the 5-y survival rate of

264 ntation (allo-HCT) is currently the standard curative treatment of acute leukemia, relapse remains un

265 ould reduce the risk of HCC recurrence after curative treatment of HBV-related HCC.

266 on margins (CRM) are the cornerstone for the curative treatment of locally advanced rectal cancer (LA

267 s remains one of the major challenges in the curative treatment of patients with cancer.

268 Novel disease biomarkers and curative treatment options are strongly needed.

269 esophagectomy appears to remain the optimum curative treatment regime in patients with locoregional

270 neous T-cell lymphoma (CTCL) are limited and curative treatment regimens are not available.

271 considering allogeneic transplantation as a curative treatment relative to other available contempor

272 nts who were receiving or recently completed curative treatment reported more symptoms and better sym

273 or cell (HSPC) gene therapy is a potentially curative treatment that represents an alternative to all

274 d patient prognosis regarded as poor because curative treatment was only available for very few leuko

275 At multivariate analysis, HCC curative treatment was the only independent predictor (H

276 Curative treatment with DAA attenuated the liver stiffne

277 as a result of rising incidence and limited curative treatment(s) for patients with advanced disease

278 years shows that, without primaquine radical curative treatment, 3 in 4 patients relapse.

279 There is no curative treatment, and current strategies proposed for

280 ate-lowering therapy, which is a definitive, curative treatment, and fewer than a half of patients ad

281 hich has an unknown pathogenesis and lacks a curative treatment, is becoming more prevalent.

282 In the absence of curative treatment, multidisciplinary care is targeted t

283 em cell (HSC) transplantation represents the curative treatment, with thalassemia-free survival excee

284 ediatric brain tumors in desperate need of a curative treatment.

285 (MS) is a chronic autoimmune disease with no curative treatment.

286 urodegenerative dementias, with no available curative treatment.

287 than did those who were further in time from curative treatment.

288 ciated with the ability to offer potentially curative treatment.

289 that has several therapeutic options but no curative treatment.

290 ses such as multiple sclerosis, which has no curative treatment.

291 ocellular carcinoma that was not amenable to curative treatment; no previous systemic treatment; and

292 ], 0.4; 95% CI, 0.2-0.9; P = 0.04), previous curative treatments (HR, 0.3; 95% CI, 0.2-0.7; P = 0.003

293 ling hallmark of chronic lung disease, lacks curative treatments at present.

294 ransplantation and gene therapy are the only curative treatments available, and the best-known progno

295 However, no curative treatments exist, suggesting that novel approac

296 nfection (CHB), and the development of novel curative treatments is urgently needed.

297 With no curative treatments presently available, retrovirally tr

298 h Administration (population enriched with 3 curative treatments) from 2008 to 2016.

299 ade therapy has demonstrated the potentially curative value of preexisting tumor-primed T cells in ca

300 Radiation therapy is beneficial but not curative, with the condition being uniformly fatal.